[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Tinkle, C.L. and Haas-Kogan, D. (2012) Hepatocellular Carcinoma: Natural History, Current Management, and Emerging Tools. Biologics, 6, 207-219. https://doi.org/10.2147/BTT.S23907
|
[3]
|
Maluccio, M. and Covey, A. (2012) Recent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma. CA: A Cancer Journal for Clinicians, 62, 394-399. https://doi.org/10.3322/caac.21161
|
[4]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
|
[5]
|
Marrero, J.A., Kulik, L.M., Sirlin, C.B., et al. (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68, 723-750.
https://doi.org/10.1002/hep.29913
|
[6]
|
Rahbari, N.N., Mehrabi, A., Mollberg, N.M., et al. (2011) Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery, 253, 453-469. https://doi.org/10.1097/SLA.0b013e31820d944f
|
[7]
|
Poon, R.T., Fan, S.T., Lo, C.M., et al. (2002) Long-Term Survival and Pattern of Recurrence after Resection of Small Hepatocellular Carcinoma in Patients with Preserved Liver Function: Implications for a Strategy of Salvage Transplantation. Annals of Surgery, 235, 373-382. https://doi.org/10.1097/00000658-200203000-00009
|
[8]
|
El-Serag, H.B. and Rudolph, K.L. (2007) Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology, 132, 2557-2576. https://doi.org/10.1053/j.gastro.2007.04.061
|
[9]
|
Sapisochin, G. and Bruix, J. (2017) Liver Transplantation for Hepatocellular Carcinoma: Outcomes and Novel Surgical Approaches. Nature Reviews Gastroenterology & Hepatology, 14, 203-217. https://doi.org/10.1038/nrgastro.2016.193
|
[10]
|
Sharma, P., Welch, K., Hussain, H., et al. (2012) Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence after Liver Transplantation in the MELD Era. Digestive Diseases and Sciences, 57, 806-812.
https://doi.org/10.1007/s10620-011-1910-9
|
[11]
|
Alshahrani, A.A., Ha, S.M., Hwang, S., et al. (2018) Clinical Features and Surveillance of Very Late Hepatocellular Carcinoma Recurrence after Liver Transplantation. Annals of Transplantation, 23, 659-665.
https://doi.org/10.12659/AOT.910598
|
[12]
|
Chok, K.S., Chan, S.C., Cheung, T.T., et al. (2011) Late Recurrence of Hepatocellular Carcinoma after Liver Transplantation. World Journal of Surgery, 35, 2058-2062. https://doi.org/10.1007/s00268-011-1146-z
|
[13]
|
Angelico, R., Parente, A. and Manzia, T.M. (2017) Using a Weaning Immunosuppression Protocol in Liver Transplantation Recipients with Hepatocellular Carcinoma: A Compromise between the Risk of Recurrence and the Risk of Rejection? Translational Gastroenterology and Hepatology, 2, 74. https://doi.org/10.21037/tgh.2017.08.07
|
[14]
|
Dulai, P.S., Singh, S., Patel, J., et al. (2017) Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Hepatology, 65, 1557-1565. https://doi.org/10.1002/hep.29085
|
[15]
|
Lee, Y.A., Wallace, M.C. and Friedman, S.L. (2015) Pathobiology of Liver Fibrosis: A Translational Success Story. Gut, 64, 830-841. https://doi.org/10.1136/gutjnl-2014-306842
|
[16]
|
Leonardi, G.C., Candido, S., Cervello, M., et al. (2012) The Tumor Microenvironment in Hepatocellular Carcinoma (Review). International Journal of Oncology, 40, 1733-1747.
|
[17]
|
Weiskirchen, R. and Tacke, F. (2016) Liver Fibrosis: From Pathogenesis to Novel Therapies. Digestive Diseases, 34, 410-422. https://doi.org/10.1159/000444556
|
[18]
|
Ahmad, O.B., Boschi-Pinto, C., Lopez, A.D., Murray, C.J., Lozano, R. and Inoue, M. (2001) Age Standardization of Rates: A New WHO Standard. World Health Organization, Geneva. http://www.who.int/healthinfo/paper31.pdf
|
[19]
|
Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462.
https://doi.org/10.1056/NEJMra1713263
|
[20]
|
Ahmad, O.B., Lopez, A.D., Murray, C.J., Lozano, R. and Inoue, M. (2017) Age Standardization of Rates: A New WHO Standard. World Health Organization, Geneva.
|
[21]
|
Tarantino, G., Magistri, P., Ballarin, R., et al. (2016) Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Frontiers in Pharmacology, 7, 387. https://doi.org/10.3389/fphar.2016.00387
|
[22]
|
Huang, J.L., Fu, Y.P., Jing, C.Y., et al. (2018) A Novel and Validated Prognostic Nomogram Based on Liver Fibrosis and Tumor Burden for Patients with Hepatocellular Carcinoma after Curative Resection. Journal of Surgical Oncology, 117, 625-633. https://doi.org/10.1002/jso.24895
|
[23]
|
Krenkel, O., Puengel, T., Govaere, O., et al. (2018) Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis. Hepatology, 67, 1270-1283. https://doi.org/10.1002/hep.29544
|
[24]
|
Trautwein, C., Friedman, S.L., Schuppan, D., et al. (2015) Hepatic Fibrosis: Concept to Treatment. Journal of Hepatology, 62, S15-S24. https://doi.org/10.1016/j.jhep.2015.02.039
|
[25]
|
Noda, Y., Kawaguchi, T., Korenaga, M., et al. (2019) High Serum Interleukin-34 Level Is a Predictor of Poor Prognosis in Patients with Non-Viral Hepatocellular Carcinoma. Hepatology Research, 49, 1046-1053.
https://doi.org/10.1111/hepr.13350
|
[26]
|
Suh, S.W. and Choi, Y.S. (2019) Influence of Liver Fibrosis on Prognosis after Surgical Resection for Resectable Single Hepatocellular Carcinoma. ANZ Journal of Surgery, 89, 211-215. https://doi.org/10.1111/ans.14732
|
[27]
|
Taura, K., Ikai, I., Hatano, E., et al. (2007) Influence of Coexisting Cirrhosis on Outcomes after Partial Hepatic Resection for Hepatocellular Carcinoma Fulfilling the Milan Criteria: An Analysis of 293 Patients. Surgery, 142, 685-694.
https://doi.org/10.1016/j.surg.2007.05.009
|
[28]
|
Sasaki, K., Shindoh, J., Margonis, G.A., et al. (2017) Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. JAMA Surgery, 152, e165059. https://doi.org/10.1001/jamasurg.2016.5059
|
[29]
|
Baeck, C., Wehr, A., Karlmark, K.R., et al. (2012) Pharmacological Inhibition of the Chemokine CCL2 (MCP-1) Diminishes Liver Macrophage Infiltration and Steatohepatitis in Chronic Hepatic Injury. Gut, 61, 416-426.
https://doi.org/10.1136/gutjnl-2011-300304
|
[30]
|
Karlmark, K.R., Weiskirchen, R., Zimmermann, H.W., et al. (2009) Hepatic Recruitment of the Inflammatory Gr1+ Monocyte Subset upon Liver Injury Promotes Hepatic Fibrosis. Hepatology, 50, 261-274.
https://doi.org/10.1002/hep.22950
|
[31]
|
Zhang, Y., Wang, R. and Yang, X. (2018) FIB-4 Index Serves as a Noninvasive Prognostic Biomarker in Patients with Hepatocellular Carcinoma: A Meta-Analysis. Medicine (Baltimore), 97, e13696.
https://doi.org/10.1097/MD.0000000000013696
|
[32]
|
Toyoda, H., Kumada, T., Tada, T., et al. (2017) Differences in the Impact of Prognostic Factors for Hepatocellular Carcinoma over Time. Cancer Science, 108, 2438-2444. https://doi.org/10.1111/cas.13406
|